INTRODUCTION {#s1}
============

Few health issues have elicited as intense debate as the relationship between selenium (Se) and the risk of cancer \[[@R1]--[@R4]\]. Synthesizing the scientific evidence on the Se-cancer relationship is difficult---there is a large abundance of literature reporting effects ranging from nutritional to toxic even for the same chemical form of Se, amount of exposure, and target species \[[@R2], [@R5]\]---and carries the risk of being labeled a selenophobic \[[@R6]\] or a selenophilic \[[@R7]\], depending on one\'s conclusions. Yet attempts to reconcile the current evidence are critically important, not only to meet the information needs of key stakeholders, including the general population and regulatory agencies, but also because the attempt can yield important lessons for epidemiology, public health, and oncology. The time trend in the number of Medline-indexed citations returned when using the search terms "selenium" and "cancer" indicates an enduring interest in this issue ([Figure 1](#F1){ref-type="fig"}).

![Number of publications per year yielded a Medline search using the terms "selenium" and "cancer" (solid line) and "selenium," "cancer," and "humans" (dotted line).](lesc31_305_f1){#F1}

Debates about the health effects of particular substances are not unusual in biomedical research, but the disputes surrounding Se have been particularly heated. At various time points in recent history, Se has been hypothesized to be a carcinogen, a cancer preventive agent, a cancer therapeutic agent, and to have no effect on human cancer. The suggestion of opposite effects of Se on health is not confined to cancer. Se has been shown to have both antioxidant and pro-oxidant activity \[[@R5]\], to be both neuroprotective and neurotoxic \[[@R8]\], a cardiovascular health promotor as well as a cardiovascular health risk factor \[[@R9]\], and has been suggested to be both an antidiabetogenic and a prodiabetogenic agent \[[@R10]\]. Overlaid on this confusing state of affairs is the fact that Se is an essential nutrient for humans; it is a constituent of more than 20 selenoproteins that play critical roles in reproduction, thyroid hormone metabolism, DNA synthesis, and protection from oxidative damage and infection \[[@R11]\].

The aims of this review are to briefly summarize past literature to provide historical perspective and critically evaluate the most recent findings on the Se-human cancer relationship emerging from epidemiologic and clinical studies and their coherence with laboratory evidence. We also briefly discuss exposure limits for Se and the prospects for Se as a cancer therapeutic agent.

EARLY LABORATORY STUDIES ON SE AND CANCER {#s2}
=========================================

Se was first implicated in the etiology of cancer in 1943 by the seminal study of Nelson and colleagues, who reported its ability to promote liver cell adenoma and carcinoma in rats \[[@R12]\]. This was followed by other reports of carcinogenic effects \[[@R13], [@R14]\], but also several studies in laboratory animals suggesting the ability of Se to inhibit cancer cell growth \[[@R15]\], leading to a large literature on the ability of Se compounds to inhibit cancer progression \[[@R1], [@R16]\]. More recent laboratory investigations have also found evidence of both cancer-enhancing and cancer-inhibiting effects of Se, depending on the amount of exposure and chemical forms \[[@R17]--[@R20]\].

EARLY ECOLOGIC STUDIES ON SE AND CANCER {#s3}
=======================================

The first hypothesis concerning the relationship of Se and human cancer arose from ecologic studies carried out in the United States and were published starting in the late 1960s. These investigations, initiated by Shamberger and colleagues \[[@R21], [@R22]\] and followed by others \[[@R23]--[@R26]\], consistently suggested an inverse association between environmental indicators of Se exposure such as forage and water Se levels or population levels of human biomarkers (Se dietary intake or blood levels) and area-level cancer rates, and were the first studies to bring the possible relationship between Se intake and cancer risk to the attention of the scientific community and the general public. Surprisingly, the weaknesses of such studies, inherent in their ecologic study design, were given little attention, and these data, together with animal studies suggesting a cancer preventive effect, had a major role in promoting the hypothesis of cancer chemoprevention by selenium.

Most ecologic studies of the Se-cancer relationship, particularly the earlier ones \[[@R27]\], had little or no control of potential confounders, and had indicators of community-level Se exposure that were of questionable reliability. More recent studies have had improved control of confounders \[[@R2], [@R27]\], and also found inverse relationships between Se exposure and risk of several site-specific cancers as well as overall cancer risk; however, the large potential for bias associated with ecologic study designs remains. Findings from ecologic studies have not been uniformly in favor of cancer chemoprevention. A direct association with environmental indicators of Se exposure has been suggested for some site-specific cancers, such as leukemia and lymphoma \[[@R26]\]. More recently, and unexpectedly, direct association between Se exposure indicators and cancer risk have been suggested by other ecologic studies, such as a direct association between breast cancer mortality and serum Se levels in 65 Chinese rural counties \[[@R28]\] and between esophageal cancer incidence and soil Se in northeastern Iran \[[@R29]\], in contrast with other recent reports \[[@R30]\], further highlighting the need for caution in evaluating the validity and reliability of the results of such studies.

In the case of Se, the weaknesses of ecologic studies far exceed those of most ecologic studies. Se local water, soil, and forage content has little influence on the Se exposure of local residents, since most individuals, particularly in Western countries including the United States, do not consume mainly locally produced foodstuffs, and therefore their diet is not directly influenced by local soil Se. Further, water Se levels may vary considerably across local wells even in very small areas, thus precluding reliable evaluation of local exposure using geographical aggregate estimates. In addition, other factors such as occupational exposures, smoking habits, and intake of methionine may greatly influence Se intake and bioavailability, further weakening the reliability of any epidemiologic studies based on aggregate assessment of exposure and outcomes.

THE NEXT STAGE: COHORT AND CASE-CONTROL STUDIES {#s4}
===============================================

Following the early ecologic studies, numerous observational studies with individual-level Se exposure assessment were conducted \[[@R2], [@R27]\]. Many of these studies had a prospective design, for example, a cohort-nested case-control study design, in an attempt to avoid one of the most common weaknesses of case-control studies, reverse causality---a disease-induced change of Se status. However, as we describe, exposure assessment is still a major issue for such studies, limiting their value in resolving the Se-cancer relationship. Given its importance, we first discuss exposure assessment issues for such studies.

Many individual-level epidemiologic studies have used biological indicators of exposure, generally toenail or blood Se content or whole blood glutathione-peroxidase activity, in specimens collected at baseline to assess overall Se exposure \[[@R2], [@R31]\]. A limitation of these common biomarkers is that Se content in specific compartments such as blood or toenails may not represent levels of Se species in tissues relevant to cancer risk; in this, we can take a lesson from studies of the Se distribution in the human central nervous system \[[@R8], [@R32]\], which have found that Se concentrations in cerebrospinal fluid may be uncorrelated with peripheral circulating Se levels ([Table 1](#T1){ref-type="table"}).

###### 

Median Values (*μ*g/l) of Se Chemical Species Identified in Blood (Serum) and Cerebrospinal Fluid (CSF) of 24 Human Subjects, with Their Squared Correlation Coefficients (r^2^) (Published and Unpublished Data from Solovyev, Berthele, and Michalke \[[@R32]\])

  Se Species                                Serum                                      CSF     r[^2^](#T1-FN2){ref-type="table-fn"}
  ----------------------------------------- ------------------------------------------ ------- --------------------------------------
  Se-cysteine                               \<LoD[^1^](#T1-FN1){ref-type="table-fn"}   \<LoD   
  Selenoprotein P                           5.19                                       0.474   0.037
  Glutathione peroxidase                    4.27                                       0.036   0.384
  Se-methionine                             0.23                                       \<LoD   
  Thioredoxin reductase                     1.64                                       0.035   0.629
  Human serum albumin Se (HSA-Se)           18.03                                      0.068   0.172
  Selenite                                  12.25                                      0.046   0.040
  Selenate                                  \<LoD                                      \<LoD   0.009
  UF[^2^](#T1-FN2){ref-type="table-fn"}−1   \<LoD                                      \<LoD   
  UF-2                                      \<LoD                                      \<LoD   
  UF-3                                      \<LoD                                      \<LoD   
  UF-4                                      6.34                                       \<LoD   
  Total                                     58.39                                      0.861   0.0002

Limit of detection.

Unknown form.

Estimation of Se dietary intake has also been used for exposure assessment. This approach has been considered by some investigators as less reliable than biological indicators, due to large variations of Se content in foodstuffs over space and time, individual differences in absorption, and the role of other sources of exposure, that is, dermal absorption and inhalation (e.g., with smoking, in occupational environments, or in coal-polluted areas). However, many epidemiologic studies \[[@R33]--[@R37]\], although not all \[[@R38]--[@R40]\], have found that estimated Se dietary intake is correlated with tissue level, such as blood or toenail Se content. It could be argued that dietary intake is superior to Se tissue content as an indication of exposure, since the different Se species are retained at very different rates in the body and they also modify their biological activity on the basis of concurrent intake of dietary factors such as methionine and other elements such as Zn, Hg, and Cd \[[@R5], [@R41]\]. Furthermore, lower persistence of some Se species in the body compared with others does not per se indicate less biological availability or lower toxicity, since carefully conducted studies in animals have demonstrated that Se retained in the body after administration of its inorganic forms can be more toxic than Se administered as organic species, for equivalent amounts of intake \[[@R42], [@R43]\]. Under this perspective, careful assessment of Se intake from diet and other sources and whenever possible its speciation would allow a better estimate of actual exposure than simple determination of overall Se content through biomarkers, which is mainly influenced by intake of organic Se.

Exposure assessment using Se-containing enzymes such as plasma selenoprotein-P or whole blood glutathione-peroxidase activity has also been suggested \[[@R44]\]. Each such indicator has particular strengths and limitations; however, in general, the use of indirect indicators such as Se-containing enzymes has serious limitations, since the relationship between their tissue levels and Se exposure is complex and not well-defined, is heavily influenced by other dietary factors, and is inducible by factors such as oxidative stress (including Se itself) \[[@R5], [@R45]--[@R48]\].

We now turn to the findings of these case-control and observational cohort studies, originally designed to elucidate the promising findings of the ecologic investigations and some of the laboratory studies. A huge number of these studies have been carried out in different countries and populations, and most of them have found either inverse or null associations between baseline Se exposure and subsequent cancer risk \[[@R2], [@R49]--[@R52]\], while a few have reported direct associations for specific cancer sites \[[@R53]--[@R58]\]. For prostate cancer, in particular, most though not all studies have indicated a beneficial effect of Se \[[@R2], [@R50]\]. The reasons of such inconsistencies are unclear. They cannot be readily ascribed to differences in Se exposure levels, since even in populations in the lower range of exposure, inverse, null, and direct associations have been found for the same cancer site, for example, lung cancer \[[@R57]--[@R60]\]. Unmeasured confounding is a key methodological issue that may explain these conflicting results of observational studies, despite the efforts of investigators to adjust for or stratify on measured potential confounders. Unmeasured confounding is a well-known problem in nutritional epidemiology due to the large number of dietary and lifestyle factors, which may co-vary with the primary variables under study or act as effect modifiers. However, the dietary or lifestyle factors responsible for the inconsistencies among observational studies have not been convincingly identified. Another important methodological issue that may explain these inconsistencies is exposure misclassification. Most observational studies have been based on determination of *total* Se in peripheral biomarkers such as blood (generally plasma or serum) or toenails. However, Se may be found in environmental matrices, including foods, usually by far the main source of exposure, as organic and inorganic compounds \[[@R3], [@R61]\], and these different chemical forms of Se have different and in some cases even opposite toxicological and nutritional effects \[[@R5], [@R62]--[@R70]\]. Moreover, some dietary factors such as methionine and trace elements such as heavy metals may considerably modify Se biological activity and metabolism \[[@R41], [@R42], [@R71], [@R72]\], and the chemical forms of Se may influence its distribution in different body tissues \[[@R27], [@R32], [@R73]--[@R75]\]; in addition, the levels found in some body tissues may not correlate with those detected by other biological indicators. Taking into account all these aspects, lack of determination of specific Se species in target organs/tissues for disease onset, and of other circulating factors influencing Se biological activity, may have created substantial misclassification of exposure, which, in the worse cases---particularly for Se compounds having lower concentrations but the highest toxicological activity such as the inorganic forms selenite and selenite \[[@R76]--[@R78]\]---may have biased the overall results. On the other hand, analytical methodologies for determination of individual Se species have only recently been developed \[[@R32], [@R79], [@R80]\] and are complex, expensive, and time-consuming. In case-control investigations based on biomarkers, exposure misclassification may also have been generated by an effect of disease itself (particularly at its advanced stages) on Se biological indicators, generally inducing a decrease in circulating Se levels but in some instances increasing Se concentrations (as the neoplastic tissue). This raises the issue of reverse causality, whose risk is inherent in this type of studies. Finally, an additional possible explanation of the different findings may be the different genetic compositions of the underlying populations, since variants of genes coding selenoproteins might modify the risk of cancer, as well as of cancer survival, associated with Se exposure \[[@R81]--[@R83]\]. Specific genotypes may modify the selenium-human cancer association \[[@R51]\] and may even switch Se from being protective to being detrimental in influencing cancer risk \[[@R84], [@R85]\].

MOVING FORWARD: RANDOMIZED CONTROLLED TRIALS {#s5}
============================================

Considering the conflicting results of observational studies and their limitations, and the strong chemopreventive effect of Se suggested by some of them, it is no surprise that randomized controlled trials (RCTs) were designed to confirm such findings. The key features of these studies and their main results are summarized in [Table 2](#T2){ref-type="table"} and [Figure 2a](#F2){ref-type="fig"}--[c](#F2){ref-type="fig"}.

![Relative risk (RR) for selected cancers in randomized, placebo-controlled trials (with 200 *μ*g of organic Se when not otherwise specified; see [Table 2](#T2){ref-type="table"} for references numbers).](lesc31_305_f2){#F2}

Some trials have been designed as multiple intervention cohort studies, administering other trace elements and vitamins or different substances \[[@R86]--[@R89]\] to participants in addition to Se, thus precluding identification of its specific activity. Other experimental studies having a "community" design selectively focused on Se activity but were characterized by lack of adequate information about potential confounders or individual-based follow-up and ascertainment of both exposure and outcome \[[@R90]--[@R92]\], thus hampering interpretation of results. We therefore do not take these studies into further consideration in the present review. Rather, we focus on RCTs that were specifically designed to estimate the effects of Se administration on cancer risk, the majority of which were carried out in specific patient populations in the United States \[[@R93]--[@R97]\] and in France \[[@R98]\], and in one case in the general U.S. population \[[@R99], [@R100]\]. The patient populations involved in such studies were nonmelanoma skin cancer patients \[[@R93]--[@R95]\], individuals at high risk of prostatic neoplasm \[[@R96], [@R97]\] or breast cancer \[[@R101]\], and organ transplant recipients \[[@R98]\]. Among these trials, the two largest, the Nutritional Prevention of Cancer (NPC) Trial and the Selenium and Vitamin E Cancer Prevention Trial (SELECT), have received the greatest attention from both the general population and the scientific community. We discuss these trials in detail.

###### 

Summary of Effect of Se Supplementation on Human Cancer Risk by Cancer Site (Dose of 200 *µ*g/Day as Organic Se When Not Otherwise Specified)

                                                                                                                                                                                                                               Placebo Group   Selenium Supplementation Group                                                                                                           
  ---------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- --------------- --------------------------------------- -------------- --------------------------------------- ----------------------------------------- -------------------------------------------------
  Any cancer                                                                                                                                                                                                                                                                                                                                                                            
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         119             659                                     77             653                                     0.63                                      (0.47--0.85)
   NPC                                     Duffield-Lillico et al., 2002 \[[@R93]\]                        Patients with history of basal or squamous cell skin cancer                                                         137             629                                     105            621                                     0.75                                      (0.58--0.97)
   NPC                                     Reid et al., 2008 \[[@R123]\]                                   Patients with history of basal or squamous cell skin cancer                                                         21              161                                     15             154                                     0.73                                      (0.35--1.48)
   NPC                                     Reid et al., 2008(400mcg/day Se) \[[@R123]\]                    Patients with history of basal or squamous cell skin cancer                                                         19              213                                     21             210                                     1.10                                      (0.57--2.17)
   SELECT                                  Lippman et al., 2009 \[[@R99]\]                                 \>50 yrs. men not at risk for prostate cancer, US, Canada and Puerto Rico                                           824             8696                                    837            8752                                    1.01                                      (0.89--1.15)[^b^](#T2-FN2){ref-type="table-fn"}
   SELECT                                  Klein et al., 2011 \[[@R100]\]                                  \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico                                         1108            8696                                    1132           8752                                    1.02                                      (0.92--1.14)[^b^](#T2-FN2){ref-type="table-fn"}
  Prostate cancer                                                                                                                                                                                                                                                                                                                                                                       
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         35              659                                     13             653                                     0.37                                      (0.18--0.71)
   NPC                                     Duffield-Lillico et al., 2003 \[[@R95]\]                        Patients with history of basal or squamous cell skin cancer                                                         42              470                                     22             457                                     0.48                                      (0.28--0.80)
   SELECT                                  Lippman et al., 2009 \[[@R99]\]                                 \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico                                         416             8696                                    432            8752                                    1.04                                      (0.87--1.24)[^b^](#T2-FN2){ref-type="table-fn"}
   SELECT                                  Klein et al., 2011 \[[@R100]\]                                  \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico                                         529             8696                                    575            8752                                    1.09                                      (0.93--1.27)[^b^](#T2-FN2){ref-type="table-fn"}
   SELECT                                  Klein et al., 2011 \[[@R100]\]                                  \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico High-grade disease (Gleason score ≥7)   133             8696                                    161            8752                                    1.21                                      (0.90--1.63)[^b^](#T2-FN2){ref-type="table-fn"}
                                           Marshall et al., 2011 \[[@R96]\]                                Men at high risk for prostate cancer, U.S.                                                                          49              134                                     48             135                                     0.91[^c^](#T2-FN3){ref-type="table-fn"}   (0.55--1.52)[^c^](#T2-FN3){ref-type="table-fn"}
                                           Marshall et al., 2011 \[[@R96]\]                                Men at high risk for prostate cancer, U.S. (only subjects for which plasma Se levels were available)                47              130                                     45             125                                     0.97                                      (0.68--1.39)
                                           Algotar et al., 2013 \[[@R97]\]                                 Men at high risk for prostate cancer, U.S. and New Zealand                                                          26              232                                     24             234                                     0.94                                      (0.52--1.70)
                                           Algotar et al., 2013 (400 mcg/day Se) \[[@R97]\]                Men at high risk for prostate cancer, U.S. and New Zealand                                                          26              232                                     23             233                                     0.90                                      (0.48--1.66)
  Bladder cancer                                                                                                                                                                                                                                                                                                                                                                        
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         6               659                                     8              653                                     1.32                                      (0.40--4.61)
   NPC                                     Duffield-Lillico et al., 2002 \[[@R93]\]                        Patients with history of basal or squamous cell skin cancer                                                         8               629                                     10             621                                     1.28                                      (0.50--3.25)
   SELECT                                  Lotan et al., 2012 \[[@R113]\]                                  \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico                                         53              8696                                    60             8752                                    1.13                                      (0.78--1.63)[^b^](#T2-FN2){ref-type="table-fn"}
  Lung cancer                                                                                                                                                                                                                                                                                                                                                                           
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         31              659                                     17             653                                     0.54                                      (0.30--0.98)
   NPC                                     Duffield-Lillico et al., 2002 \[[@R93]\]                        Patients with history of basal or squamous cell skin cancer                                                         35              629                                     25             621                                     0.74                                      (0.44--1.24)
   SELECT                                  Lippman et al., 2009 \[[@R99]\]                                 \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico                                         67              8696                                    75             8752                                    1.12                                      (0.73--1.72)[^b^](#T2-FN2){ref-type="table-fn"}
   SELECT                                  Klein et al., 2011 \[[@R100]\]                                  \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico                                         92              8696                                    94             8752                                    1.02                                      (0.70--1.50)[^b^](#T2-FN2){ref-type="table-fn"}
  Colorectal cancer                                                                                                                                                                                                                                                                                                                                                                     
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         19              659                                     8              653                                     0.42                                      (0.18--0.95)
   NPC                                     Duffield-Lillico et al., 2002 \[[@R93]\]                        Patients with history of basal or squamous cell skin cancer                                                         19              629                                     9              621                                     0.46                                      (0.21--1.02)
   SELECT                                  Lippman et al., 2009 \[[@R99]\]                                 \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico                                         60              8696                                    63             8752                                    1.05                                      (0.66--1.67)[^b^](#T2-FN2){ref-type="table-fn"}
   SELECT                                  Klein et al., 2011 \[[@R100]\]                                  \>50 yrs. men not at risk for prostate cancer, U.S., Canada and Puerto Rico                                         75              8696                                    74             8752                                    0.96                                      (0.63--1.46)[^b^](#T2-FN2){ref-type="table-fn"}
  Breast cancer                                                                                                                                                                                                                                                                                                                                                                         
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         3               659                                     9              653                                     2.88                                      (0.72--16.5)
   NPC                                     Duffield-Lillico et al., 2002 \[[@R93]\]                        Patients with history of basal or squamous cell skin cancer                                                         6               629                                     11             621                                     1.89                                      (0.69--5.14)
                                           Lubinski et al., 2011 \[[@R101]\] (250 *µ*g/day inorganic Se)   Women with a BRCA1 mutation                                                                                         45              \-[^d^](#T2-FN4){ref-type="table-fn"}   60             \-[^d^](#T2-FN4){ref-type="table-fn"}   1.4                                       (0.9--2.0)
  Melanoma                                                                                                                                                                                                                                                                                                                                                                              
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         8               659                                     8              653                                     0.97                                      (0.32--2.96)
   NPC                                     Duffield-Lillico et al., 2002 \[[@R93]\]                        Patients with history of basal or squamous cell skin cancer                                                         9               629                                     11             621                                     1.18                                      (0.49--2.85)
  Nonmelanoma skin cancer                                                                                                                                                                                                                                                                                                                                                               
   NPC                                     Duffield-Lillico et al., 2003 \[[@R94]\]                        Patients with history of basal or squamous cell skin cancer                                                         not provided    629                                     not provided   621                                     1.17                                      (1.02--1.34)
                                           Dreno et al., 2007 \[[@R98]\]                                   Recent organ transplant patients                                                                                    2               93                                      6              91                                      3.07                                      (0.5--31.1)
   NPC                                     Reid et al., 2008 \[[@R123]\]                                   Patients with history of basal or squamous cell skin cancer                                                         80              161                                     99             154                                     1.49                                      (1.10--2.03)
   NPC                                     Reid et al., 2008(400mcg/day Se) \[[@R123]\]                    Patients with history of basal or squamous cell skin cancer                                                         108             213                                     98             210                                     0.88                                      (0.66--1.16)
  NM skincancer---Squamouscell carcinoma                                                                                                                                                                                                                                                                                                                                                
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         190             659                                     218            653                                     1.14                                      (0.93--1.39)
   NPC                                     Duffield-Lillico et al., 2003 \[[@R94]\]                        Patients with history of basal or squamous cell skin cancer                                                         not provided    629                                     not provided   621                                     1.25                                      (1.03--1.51)
   NPC                                     Reid et al., 2008 \[[@R123]\]                                   Patients with history of basal or squamous cell skin cancer                                                         42              161                                     65             154                                     1.76                                      (1.18--2.66)
   NPC                                     Reid et al., 2008 (400mcg/day Se) \[[@R123]\]                   Patients with history of basal or squamous cell skin cancer                                                         53              213                                     56             210                                     1.05                                      (0.71--1.56)
  NM skin cancer---Basal cellcarcinoma                                                                                                                                                                                                                                                                                                                                                  
   NPC                                     Clark et al., 1996 \[[@R102]\]                                  Patients with history of basal or squamous cell skin cancer                                                         350             659                                     377            653                                     1.10                                      (0.95--1.28)
   NPC                                     Duffield-Lillico et al., 2003 \[[@R94]\]                        Patients with history of basal or squamous cell skin cancer                                                         not provided    629                                     not provided   621                                     1.09                                      (0.94--1.26)
   NPC                                     Reid et al., 2008 \[[@R123]\]                                   Patients with history of basal or squamous cell skin cancer                                                         69              161                                     75             154                                     1.20                                      (0.85--1.68)
   NPC                                     Reid et al., 2008(400mcg/day Se) \[[@R123]\]                    Patients with history of basal or squamous cell skin cancer                                                         83              213                                     76             210                                     0.90                                      (0.65--1.24)

Relative risk of cancer in in supplemented vs. nonsupplemented individuals.

99% confidence interval.

Unpublished data (courtesy of Dr. James Marshall).

1135 women with a BRCA1 mutation randomized to Se or placebo.

The Nutritional Prevention of Cancer (NPC) Trial {#s6}
------------------------------------------------

The NPC trial \[[@R93]--95, 102--[@R104]\] was designed to test the hypothesis that dietary supplementation with Se at 200 *µ*g/day may decrease cancer risk. The study participants (n = 1312) were patients with recent (1-year) diagnosis of basal or squamous cell skin cancer, life expectancy of at least 5 years, and no treatment for internal cancers in the past 5 years. Se was administered as selenized baker\'s yeast, which contains organic Se in the form of selenomethionine (∼60%) and other selenoproteins \[[@R103]\]. The primary outcomes were the incidence of basal cell and squamous cell skin cancer; secondary outcomes included incidence of all cancers and of some major site-specific cancers. Patient recruitment occurred in 1983--1991, and the official end of the blinded treatment period was February 1, 1996. Final results were published in 2002--2003 \[[@R93]--[@R95]\]. A preliminary analysis was published in 1996 based on follow-up data through December 1, 1993, following the recommendation of the trial\'s Safety Monitoring and Advisory Committee in 1994 to unblind the study and present the results for the first 10-year period \[[@R102]\]. We focus on the final results, which are based on longer follow-up.

The final results of the NPC trial, reported in [Table 2](#T2){ref-type="table"} and [Figure 2a](#F2){ref-type="fig"}--[c](#F2){ref-type="fig"}, are complex to interpret. There was an excess risk of squamous cell carcinoma (RR 1.25, 95% CI 1.03--1.51) and a slightly increased risk of basal cell carcinoma (RR 1.09, 95% 0.94--1.26), yielding an excess risk of overall nonmelanoma skin cancer of 17% (95% CI 2%--34%) and leading to the conclusion that Se increased the risk of total nonmelanoma skin cancer \[[@R94]\]. In contrast, the risk of all cancers (RR 0.75, 95% CI 0.58--0.97), prostate (RR 0.48, 95% CI 0.28--0.80), lung (RR 0.74, 95% CI 0.44--1.24), and colorectal (RR 0.46, 95% CI 0.21--1.02) cancers \[[@R93], [@R103]\] was decreased. For lung cancer, an analysis according to baseline plasma Se showed that the inverse association was confined to subjects in the lowest tertile, which was \<106 *μ*g/l \[[@R103]\]. Some cancer sites suggested an increased risk associated with Se supplementation, but estimates were generally statistically unstable due to the low number of cases: among these were breast cancer (RR 1.89, 95% CI 0.69--5.14) and, with much lower RRs, melanoma, bladder, and lymphoma and leukemia. Further analyses on prostate cancer revealed very different RRs according to baseline plasma Se, ranging from RR values as low as 0.14 (95% CI 0.03--0.61) among subjects in the lowest tertile of plasma Se (≤106.4 *μ*g/l) up to 1.14 (95% CI 0.51--2.59) for plasma Se \> 123.2 *μ*g/l, but the risk reduction was nearly entirely confined to subjects with prostate specific antigen (PSA) ≤4 ng/ml \[[@R95]\]. In addition, further analysis stratified by treatment arm showed a weak inverse association between baseline Se and subsequent prostate cancer risk among placebo participants but a direct association among Se-treated participants \[[@R105]\]. After adjusting for some differences between treatment groups, the positive association between Se administration and prostate cancer risk remained strong \[[@R105]\], thus suggesting an increased risk among subjects with higher baseline plasma Se, in sharp contrast to the preliminary results of the trial \[[@R102]\] and the findings in placebo-treated subjects \[[@R105]\].

The NPC results, particularly the preliminary ones, received widespread attention from both the public and the scientific community (more than 2500 citations in Google Scholar for its first 1996 report as of July 2013), with emphasis placed on the "beneficial" findings for all cancers and prostate cancer incidence and the concerning results for the primary outcome, nonmelanoma skin cancer, either overlooked or dismissed. This lack of attention probably occurred because such results were not consistent with preexisting expectations: Se was one of most promising dietary factors in chemoprevention, the first prospective studies carried out during the 1980s had suggested an association between Se exposure indicators at baseline and subsequent cancer risk \[[@R60], [@R106]--[@R109]\], and Se had proven effective in inhibiting cancer cell growth in several animal models (although such reasoning ignored the carcinogenic activity of some Se compounds suggested by a few of these studies).

The Selenium and Vitamin E Cancer Prevention Trial (SELECT) {#s7}
-----------------------------------------------------------

The SELECT trial was a large-scale attempt to evaluate the activity of two promising chemopreventive agents, Se and vitamin E, for prostate cancer prevention \[[@R110]--[@R112]\]. This trial recruited more than 35,000 men from 427 sites in the United States, Canada, and Puerto Rico; eligibility criteria were ≥50 years for black men and ≥55 for all others, a PSA value of 4.0 ng/l or less, and a digital rectal examination not suspicious for prostate cancer. Recruitment was from August 22, 2001 through June 24, 2004, and three reports of the study results have been published to date: one concerning the main outcomes after follow-up to Oct 23, 2008 \[[@R99]\], the second one updating the results with an (unblinded) follow-up until July 5, 2011 \[[@R100]\], and the third one reporting RR of bladder cancer \[[@R113]\].

SELECT study participants were randomized to oral Se as selenomethionine (200 *μ*g/day), vitamin E, Se plus vitamin E or placebo. The Se only and placebo arms included 8752 and 8696 patients who could be included in the primary analysis, respectively, and who were also followed in the updated follow-up with a person-time increase of 23%. The follow-up was extended beyond the primary outcome, prostate cancer incidence, to include cardiac events, diabetes, severe or life-threatening (grade 3 or 4) events, and minor side effects potentially related to the study supplements: alopecia, dermatitis, fatigue, halitosis, nail changes, and nausea. The originally planned minimum and maximum follow-up was 7 and 12 years, but the actual average follow-up periods were 5.5 years until the end of the blinded follow-up with discontinuation of Se supplementation and 7.1 until the end of subsequent follow-up to report additional postexposure events \[[@R99], [@R100]\]. This shorter follow-up compared to that originally planned was due to an unanticipated interruption of the trial, due to the recommendation of the independent Data Safety Monitoring Committee to discontinue the study because of its inefficacy in risk reduction and concern about increased risk of prostate cancer in vitamin E-supplemented participants and of type 2 diabetes in the Se-treated participants \[[@R99], [@R100]\], an observation that echoed the marked increase in diabetes risk observed after Se administration in the NPC trial \[[@R114]\].

Overall, the results of the SELECT trial, summarized in [Table 2](#T2){ref-type="table"} and [Figure 2a](#F2){ref-type="fig"}--[b](#F2){ref-type="fig"}, have so far provided strong evidence against any cancer-prevention effect in this study population \[[@R115]\]. Overall relative risk of cancer was 1.01 (99% CI 0.89--1.15), with a slightly and statistically imprecise increased risk of prostate cancer (RR 1.04, 99% CI 0.87--1.24), lung cancer (RR 1.12, 99% CI 0.73--1.72), and colorectal cancer (RR 1.05, 99% CI 0.66--1.67), and little evidence of altered risk for the other primary neoplasms (excluded nonmelanoma skin cancer) (RR 0.99, 95% CI 0.77--1.17) \[[@R99], [@R100]\]. An analysis limited to the risk of aggressive prostate cancer (Gleason score ≥7) showed an excess risk of high-grade disease among Se-treated subjects (RR = 1.21, 99% CI 0.90--1.63) \[[@R100]\], this possibly being the most concerning finding of the SELECT study \[[@R115]\].

Bladder cancer incidence, despite being one of the site-specific cancers most strongly associated with Se status in observational cohort studies, was not decreased by Se treatment but rather was slightly increased (RR 1.13), although the estimate was statistically very imprecise (99% CI 0.78--1.63) \[[@R113]\].

NPC vs. SELECT: Why the Conflicting Results? {#s8}
--------------------------------------------

Why did the Se-supplemented participants in the NPC trial exhibit a reduced risk of cancer while those in the second larger SELECT trial did not? One possibility is the underlying difference in populations; the NPC trial enrolled patients with nonmelanoma skin cancer whereas the SELECT trial participants, although male only, more closely resembled the general population, presenting the possibility of specific risk factors or behavioral profiles interacting with Se to modify some cancer preventive effect.

Another possibility is the different ranges of Se exposure in the two study populations, with the patients enrolled in NPC exhibiting a lower average exposure than SELECT participants. This hypothesis is interesting but unconvincing for several reasons. The first is the small difference in median intake between the two populations, of about 23 *µ*g/l, which corresponds to about 15 *µ*g/day in dietary intake \[[@R116]\], a small difference when compared to the large range of intake across different Western populations, ranging from an average of 20--40 *µ*g/day in Italian, Austrian, and French populations to ≥100 *µ*g/day in some U.S. and Japanese populations (excluding supplements) \[[@R116]--[@R118]\]. Under the same perspective, the very different results obtained in the NPC across tertiles of plasma Se for all cancers and for prostate cancer risk in Se-treated subjects, ranging from −76% in the bottom category to +14% in the highest category despite an inter-tertile range as small as 16.8 *µ*g/l (around 11 *µ*g/day of dietary Se intake), make it biologically implausible to ascribe such extreme variations in cancer RR to such small differences in exposure, unless we assume that 120 *µ*g/l of plasma Se represents a critical threshold for cancer risk. Any small change of a few *µ*g of dietary Se intake from this amount would therefore imply remarkable changes in cancer risk, but no such effects have ever been described in ecologic or individual-based epidemiologic studies despite variations in individual intakes that range into the hundreds of micrograms. This hypothesis also finds little support from observational studies concerning the effects of Se supplementation in populations with much lower average intakes of Se, such as the trends in prostate cancer incidence in Finland following nationwide Se supplementation compared with other Nordic countries, which did not show any beneficial effect \[[@R27]\]; from the lack of any reduction in mortality from prostate cancer within an Italian population naturally exposed to inorganic hexavalent Se \[[@R119]\]; and from the results of a recent phase III trial by Marshall and colleagues in high-risk individuals for prostate cancer, focusing on RRs observed in those with baseline plasma Se in the \<106 and 106--132 *μ*g/l categories \[[@R96]\].

Further weakening the possibility that such small differences in average intake may explain the different results of the two trials is the observation that toxicity of the Se supplements occurred in both the NPC and SELECT trials: an excess risk of glaucoma and diabetes in the NPC study \[[@R114], [@R120]\], and of dermatologic abnormalities and diabetes in the SELECT trial \[[@R99]\], the latter being one of the reasons for interrupting the trial; the risk of diabetes subsequently decreased following discontinuation \[[@R100]\]. Occurrence of toxicity indicates a comparable activity of Se in the two trials, an observation that weakens the hypothesis of marked differences in exposure.

To facilitate interpretation of the results of the two trials, some further analyses of the SELECT trial data would be highly informative. In particular, we urge analyses as to whether the overall risk of cancer and risk of site-specific cancers varies by baseline Se exposure level, and whether the risk of nonmelanoma and melanoma skin cancer is associated with Se supplementation \[[@R94], [@R98], [@R121]\].

Last, a potentially severe bias has been acknowledged by the NPC trial investigators, and it may at least partially explain the impressive results obtained in that trial for prostate cancer and subsequently unconfirmed by the other experimental studies \[[@R95], [@R96]\]. For unknown reasons, presumably by chance, the NPC participants randomized to Se were later found to have been less biopsied than individuals on placebo following a PSA test at baseline or in the follow-up (14% vs. 35% in the Se and placebo groups, respectively) \[[@R95], [@R96]\], thus exposing the Se supplementation arm of the trial to risk of under-detection of prostate cancer. The investigators tried to adjust the analysis for this potentially serious bias \[[@R95]\], but the extent to which this bias may have occurred is unclear and remains a critical limitation of the NPC study. A role of unmeasured confounders and of the limitations of secondary analyses (all outcomes other than nonmelanoma skin cancer primary occurrence) have also been hypothesized as potentially explaining at least some of the beneficial results on prostate cancer reported by the NPC trial \[[@R96]\]. However, these factors are unlikely to fully explain the trial results since ascertainment of the secondary outcomes was apparently satisfactory and unbiased in the NPC trial, and since claims about limitations of multiple comparisons are not convincing from an epidemiologic perspective \[[@R122]\].

Other Randomized Controlled Trials {#s9}
----------------------------------

A small ancillary study of NPC, involving patients enrolled at the Macon, GA site, added an arm assigning 400 *μ*g/day Se supplementation in order to evaluate the effects of high Se exposure and possible dose-response trends \[[@R123]\]. The results showed a possible limited decrease of risk of nonmelanoma skin cancer in the 400 *μ*g Se supplemented individuals (RR 0.88, 95% CI 0.66--1.16), compared with the excess incidence observed in the 200 *μ*g/day participants (RR 1.49, 95% CI 1.10--2.03), and no indication of decreased all-cancer incidence as seen in the NPC main results, with a RR of 1.10 (95% CI 0.57--2.17) ([Figure 2](#F2){ref-type="fig"}--[c](#F2){ref-type="fig"}). These results appear to weaken the NPC findings, although they lack statistical precision.

A trial carried out in a French population of 184 organ graft recipients, considered to be at high risk of premalignant and malignant epithelial lesions, unexpectedly detected a higher incidence of skin cancer in the 91 Se-treated patients (6 cases, 6.6%) than in the 93 placebo patients (2 cases, 2.2%, *P* = 0.15) during 5-year follow-up, the first 3 of which including daily supplementation with 200 *μ*g Se as selenized yeast \[[@R98]\] ([Figure 2](#F2){ref-type="fig"}--[c](#F2){ref-type="fig"}). Thus this study suggests an increased risk of skin cancer, mirroring the results of the NPC study \[[@R94]\] and of some although not all observational studies \[[@R55], [@R121]\].

Another randomized double-blind trial of considerable interest was conducted in Poland with a group of healthy women who were carriers of the BRCA1 mutation and thus at high risk for breast cancer \[[@R101]\]. Lubinski and colleagues randomized 1135 female BRCA1 mutation carriers to 250 *μ*g/day of Se as selenite or placebo for 6 to 62 months (median follow-up 35 months). During follow-up, 60 incident breast cancers were diagnosed among Se-supplemented women in comparison with 45 cases among placebo-administered women (RR 1.4, 95% CI 0.9--2.0) \[[@R101]\]. Such results, which were mirrored in findings on primary breast cancer, contralateral breast cancer, and ovarian cancer, suggest not just a lack of any beneficial effect of Se on breast cancer in these high-risk women but the possibility of increased risk.

Two phase III trials have published findings on the effect of Se on prostate cancer risk for high-risk individuals, which distinguishes these studies from the SELECT trial. Results of these studies, and more generally of the trials investigating prostate cancer risk, are reported in [Figure 2](#F2){ref-type="fig"}--[b](#F2){ref-type="fig"}. The first study, coordinated by the Southwest Oncology Group \[[@R96]\], randomized 423 men with high-grade prostatic intraepithelial neoplasia to 200 *μ*g/day Se as selenomethionine or placebo. After a treatment period with follow-up of 3 years, the incidence of prostate cancer in the two groups was nearly identical (48/135 \[35.6%\] in the Se group vs. 49/134 \[36.6%\] in the placebo group). There was little evidence of modifying effects of baseline plasma Se status on prostate cancer risk. In fact, lower risk emerged in the bottom (\<106 *μ*g/l) and top (\>162 *μ*g/l) quartiles of plasma Se, where RRs were 0.82 (95% CI 0.40--1.69) and 0.91 (95% CI 0.45--1.84), respectively, while individuals in the second quartile (106--132 *μ*g/l) showed a RR of 1.38 (95% CI 0.68--2.78). When the study sample was stratified by Gleason score of diagnosed prostate cancer, there was a tendency toward more aggressive tumors among Se-treated subjects. Overall, the authors concluded there was no effect of Se supplementation on prostate cancer risk in this high-risk population, although they did not entirely rule out the possibility of a beneficial effect in the lowest category of Se exposure. These results are similar to results from a recently reported Canadian phase III trial of patients with high-grade prostatic intraepithelial neoplasia, in which 3-year supplementation with vitamin E, soy, and Se (100 *μ*g/day) was associated with a prostate cancer RR of 1.12 (95% CI 0.71--1.76) \[[@R124]\].

A second phase III trial, the Negative Biopsy Study, enrolled individuals from the United States and New Zealand at high risk of prostate cancer (PSA \>4 ng/ml and/or suspicious digital rectal examination and/or PSA velocity \>0.75 ng/ml/year) but with a prostate biopsy negative for cancer or high-grade intraepithelial neoplasia, who were randomized to 200 or 400 *μ*g/day Se as selenized yeast or placebo \[[@R125]\]. The results of this 5-year trial \[[@R97]\] suggested no effect of Se treatment on prostate cancer incidence, which was 11.3% (26 cases) among 228 placebo-randomized subjects, 10.3% (24/233) among subjects receiving 200 *μ*g/day Se, and 10% (23/230) among those supplemented with 400 *μ*g/day Se. No effect of Se status at baseline on risk emerged, despite the fact that the lowest category had a plasma Se concentration of less than 101.1 *μ*g/l. Additionally, little evidence of any effect of the Se treatment on PSA velocity emerged. Therefore, it is difficult not to agree with authors\' conclusion that "Selenium supplementation appeared to have no effect on the incidence of prostate cancer in men at high risk. In conjunction with results of other studies, these data indicate that selenium supplementation may not have a role in prostate cancer chemoprevention" \[[@R97]\].

Lack of replication of the original NPC results by the SELECT trial, the results of two phase III trials of high prostate cancer risk patients, and the weakening results of the NPC trial itself over time indicate that prospective observational studies suggesting a beneficial effect of baseline Se status on subsequent prostate cancer risk \[[@R50]\] were likely biased by unmeasured confounders, and that Se does not modify prostate cancer risk. However, the possibility of modifying effects of specific genotypes \[[@R126]\] or of possible adverse effects of very low and very high Se exposures deserve further investigation. This may be possible using SELECT trial data and biological specimens (blood and toenails) to assess baseline Se status in study participants.

Over and above these null findings, recent findings of observational studies suggest extreme caution is needed when considering the effect of Se-containing supplements on prostate cancer risk. In fact, cohort and case-control studies have shown an unexpectedly increased prostate cancer risk among Se-treated subjects with the highest baseline exposure levels \[[@R105]\], excess risk associated with multivitamin use only among Se supplements use \[[@R127]\], an excess prostate cancer risk associated with Se self-supplementation (OR 2.2 with 95% CI 1.2--4.2 among consumers for ≥10 yrs. of Se supplements) \[[@R128]\], and finally a higher risk of aggressive disease in patients with higher plasma Se levels \[[@R85]\].

Results of a Natural Experiment on Selenium Exposure {#s10}
----------------------------------------------------

Natural experiments, of which Snow\'s study on cholera remains the archetype, have long enjoyed a privileged position in environmental epidemiology, since they allow the study of toxic substances that cannot be administered to humans for ethical reasons or that may require such long periods of exposure as to make them infeasible \[[@R129]\]. Such a natural experiment occurred in the Northern Italy community of Reggio Emilia, where the Rivalta neighborhood was supplied from 1972 to 1988 with municipal tap water containing unusually high levels of Se in its inorganic hexavalent form, selenate, which was the only distinctive chemical characteristics compared to drinking water distributed in the remaining municipal territory \[[@R119], [@R130]\]. The Rivalta residents also had a very similar distribution of demographic characteristics compared with the municipal population, suggesting limited potential for bias \[[@R119], [@R130]\]. Results of cohort studies carried out among long-term consumers of this high-Se tap water are summarized in [Figure 3](#F3){ref-type="fig"}. Overall, no beneficial effect on mortality from cancer or other chronic diseases emerged: cancer mortality, in fact, was slightly increased (RR 1.20, 95% CI 1.01--1.41), with excess mortality from melanoma and colorectal cancer in the whole cohort, kidney cancer in males and lympho-hematopoietic malignancies in females \[[@R119]\], and further confirmation of the increased melanoma risk from an incidence study \[[@R121]\]. Prostate cancer mortality was not decreased, but rather increased, among exposed residents (RR 1.40, 95% CI 0.45--3.39).

![Relative risk (RR) for selected cancers in a natural experiment investigated in Reggio Emilia, northern Italy, where residents consumed drinking water with high inorganic hexavalent Se content (around 8 *μ*g/l) as only distinctive feature (Vinceti et al., 1995, 1998, and 2000 \[[@R119], [@R121], [@R130]\]).](lesc31_305_f3){#F3}

Overall, these findings suggest no beneficial effect of Se on cancer risk, but rather the potential for adverse effects. These results, however, have to be considered specific for the inorganic hexavalent form of Se, whose biological properties may be markedly different from those of other chemical forms of Se such as selenomethionine, an organic form commonly used in human trials. Absolute amounts of Se exposure across the different chemical species cannot be directly compared, as demonstrated by laboratory studies that show that toxicity of inorganic (tetravalent) Se greatly exceeds that of organic Se \[[@R131]\]. However, these results are of interest since they allow assessment of the effect of the Se form usually found in drinking water, the inorganic hexavalent one, on cancer risk, and allow risk assessment of such sources of exposure \[[@R132]\].

WHAT LEVEL OF SE EXPOSURE IS "SAFE"? {#s11}
====================================

Given the nutritional role of Se and its possible low-dose toxic effects, the questions arise: What level of Se exposure in humans is needed for adequate nutrition, and at what level does Se exposure carry health risks? These are open questions, as demonstrated by the different upper and lower safe limits that have been proposed by various agencies, institutions, and investigators \[[@R133], [@R134]\], for both nutritional \[[@R135]\] and toxicological \[[@R5]\] effects, such as for Se drinking water standards \[[@R132]\].

Many current standards are based on outdated approaches and evidence. For example, one frequently used indicator of a "safe" Se exposure level and of a nutritional range of intake is the Se-induced increases and maximization of selenoproteins such as the Se-containing glutathione-peroxidases. We agree with a World Health Organization research group that such an approach should be regarded with extreme caution \[[@R135]\]. Recent studies indicate the complexity of this issue at the molecular level \[[@R136]\]. Maximization of Se-containing glutathione-peroxidases has never been demonstrated to be beneficial, and more generally, maximal expression of antioxidant enzymes should not be considered beneficial for human health unless a sound epidemiologic basis has been provided for this \[[@R5], [@R137]\]. Epidemiologic data suggest adverse health effects of Se at levels lower than those required to maximize selenoprotein expression \[[@R114], [@R119], [@R138], [@R139]\], and biochemical studies have long indicated that increased selenoprotein activity, such as in the case of glutathione-peroxidases, is driven not only by increased Se availability but also by oxidative stress induced by Se itself or by other environmental or biological stressors \[[@R45]--[@R48], [@R140], [@R141]\]. In line with this hypothesis, Se supplementation has been shown to increase levels of some proteins in adult men including clusterin \[[@R142]\], an enzyme that may be induced by oxidative stress \[[@R143], [@R144]\], and recent cross-sectional studies confirmed a direct relationship between Se exposure and oxidative stress biomarkers \[[@R145], [@R146]\].

Perhaps the best available evidence on toxic effects of Se and the levels of intake associated with them comes from observations---sometimes entirely unexpected---in human experimental studies \[[@R94], [@R99], [@R104], [@R114], [@R120]\]. Currently, the main concerns of adverse effects of Se exposure \[[@R115], [@R147]\] are an excess of skin cancer \[[@R94], [@R98]\], diabetes \[[@R99], [@R114], [@R139]\], and dermatologic alterations \[[@R99]\]; increased risk of glaucoma \[[@R120], [@R148], [@R149]\] and amyotrophic lateral sclerosis \[[@R8], [@R150]\] may also occur after low-dose overexposure to organic and inorganic Se, respectively, consistent with laboratory evidence \[[@R45], [@R151], [@R152]\]. Toxicity of inorganic Se appears to be higher than toxicity of organic forms, in line with observations from laboratory studies \[[@R67], [@R131], [@R153]\], possibly being as low as around 20 *μ*g/day on the basis of epidemiologic observations in long-term consumers of drinking water with high content of hexavalent Se \[[@R119], [@R154]\], which represents one of the few natural sources of exposure to this inorganic Se form. Additional consequences of low-dose Se overexposure may be other endocrine abnormalities or adverse effects to other organs \[[@R5], [@R155]\] and down-regulation of phase 2 genes \[[@R156]\], although evidence for these effects and identification of the thresholds of exposure involved have not been convincingly provided so far.

Currently proposed "safe" upper limits are not convincingly "safe" by current evidence; for example, the safe upper limit of intake of 400 *μ*g/day in adults suggested in 2000 by the Institute of Medicine \[[@R133]\] appears inadequate to protect human health in light of the SELECT trial results showing toxic effects of (organic) Se exposure at around 300 *μ*g/day \[[@R99]\], and other epidemiologic studies for organic Se and inorganic Se, with the latter being especially of concern for toxicity at such levels \[[@R5], [@R114], [@R139], [@R150], [@R157], [@R158]\]. Therefore, although the 2009 statement by Platz and Lippman that "At present, we do not know enough to determine how much selenium any man or woman should receive from the diet or a supplement" \[[@R159]\] is certainly and unfortunately true, the epidemiologic evidence from the most recent studies suggest that the safe range of intake of dietary Se is much lower than anticipated for the organic Se forms and much, much lower for inorganic species \[[@R5]\].

SELENIUM AS A POTENTIAL CANCER THERAPEUTIC AGENT {#s12}
================================================

The fading promise of a cancer-preventive effect of Se has been accompanied by rising interest in its potential ability to reduce cancer recurrence or to directly treat cancer in diagnosed patients, in line with a larger interest in the possible therapeutic properties of Se for various diseases \[[@R160]\].

The objective of preventing cancer recurrence is relatively new and differs from the objective of the NPC trial, which aimed to assess whether Se could reduce the occurrence of new cancers in nonmelanoma skin cancer patients rather than the risk of recurrence \[[@R102]\]. One study evaluating this new objective is the SELEnium and BLAdder cancer Trial (SELEBLAT), a phase III randomized, placebo-controlled, double-blind trial designed to assess the ability of Se to reduce recurrences of noninvasive transitional bladder carcinoma \[[@R161]\]. This trial is currently ongoing, and its findings, whether negative or positive, will certainly add to the debate about Se.

The ability of certain Se species to exert toxic effects on cancer cell growth has been demonstrated in a number of laboratory studies \[[@R162]--[@R171]\], leading to interest in the use of Se compounds as anticancer therapeutic agents, possibly as additions to standard chemotherapeutic regimens \[[@R165], 172--[@R174]\]. Some Se compounds have been shown to exert specific activities against cancer cells compared to normal cell \[[@R175]\], although these findings have not always been confirmed \[[@R176]\]. The number of human studies in this area is still very limited. A trial conducted in non-Hodgkin lymphoma patients reported that the addition of selenite to chemotherapy appeared to reduce recurrence risk \[[@R177]\]. On the other hand, a study involving stage-I nonsmall cell lung cancer patients failed to show beneficial results on risk of second primary tumors \[[@R178]\], and self-administration of Se supplements did not reduce recurrence outcomes among prostate cancer patients enrolled in the TAX 327 study \[[@R179]\]. On a cautionary note, a review of the use of dietary antioxidant supplementation during conventional chemotherapy and radiation therapy concluded that the use of such supplements should be discouraged because of the possibility of tumor protection and reduced survival \[[@R180]\].

The current evidence is too limited and inconsistent \[[@R181]\] to allow for an adequate assessment of Se as an anticancer agent and to justify its administration in cancer therapy, although this issue remains relevant and merits further evaluation. The complexity of this issue is highlighted by a recent study in mice, which showed that organic Se supplementation reduced and delayed breast cancer metastasis while selenite exacerbated it \[[@R182]\], confirming again that it is of utmost importance to consider the chemical form-specific effects of Se. Further studies and particularly human trials, taking into account clinical disease stage and genetic factors, are required to better investigate the utility and safety of Se compounds as cancer therapeutic agents.

FINAL CONSIDERATIONS {#s13}
====================

The trajectory of opinion on the relationship between Se and cancer over the years could be encapsulated in the study of lung cancer. Studies suggested a beneficial effect of Se on lung cancer risk until a decade ago \[[@R183]\], when further studies \[[@R99]\] failed to substantiate such an effect. Further, a recent observational study found a direct relationship between Se exposure and risk \[[@R58]\], mirroring previous results obtained in a U.S. study \[[@R53]\], and Se has now been added to the list of initially promising but ultimately unsuccessful---and possibly harmful---preventive agents for lung cancer \[[@R178], [@R184]\]. In Se, we have witnessed what has now become a common occurrence in nutritional epidemiology, the failure of micronutrient dietary supplements to show beneficial effects on human health \[[@R185]--[@R187]\].

Overall, experimental human studies indicate that Se does not reduce cancer risk and may increase risk of some site-specific cancers such as skin neoplasms, and no convincing evidence has so far been provided that individuals with "low" Se intake, that is, in the order of 20--70 *μ*g/day, may reduce cancer risk by increasing their Se exposure. Taking into account the potential for harm at very low levels of intake, no dietary or environmental supplementation with this metalloid may be currently recommended for cancer prevention from either an individual or a public health perspective.
